

EFFECTIVE DATE: 10|01|2019

POLICY LAST UPDATED: 06|04|2019

OVERVIEW

Gamifant™ (emapalumab-lzsg) is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.

This policy is applicable to BlueCHiP for Medicare products only. For Commercial Products, see related policy section.

MEDICAL CRITERIA

Initial Evaluation

Gamifant™ (emapalumab-lzsg) will be approved when ALL of the following are met:

1. Work up for the diagnosis of primary hemophagocytic lymphohistiocytosis (HLH) was started prior to initiating therapy

AND

2. The patient's primary HLH is refractory to a conventional therapy regimen (e.g. includes immunosuppressive or pro-apoptotic chemotherapy [e.g. etoposide, corticosteroids, cyclophosphamide, cyclosporine, anti-thymocyte globulin, methotrexate])

AND

3. The patient is receiving concomitant dexamethasone therapy

AND

4. The prescriber is a specialist in the area of the patient's diagnosis (e.g. hematologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

AND

5. The patient does NOT have any FDA labeled contraindications to the requested agent

AND

6. The requested dose is within FDA labeling

Length of Approval: 12 months

Renewal Evaluation

Gamifant™ (emapalumab-lzsg) will be approved when ALL of the following are met:

1. The patient has been previously approved for the requested agent through the Medical Drug Criteria approval process

AND

2. The patient has had clinical benefit with the requested agent

AND

3. The patient is receiving concomitant dexamethasone therapy

AND

4. The prescriber is a specialist in the area of the patient's diagnosis (e.g. hematologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

AND

5. The patient does NOT have any FDA labeled contraindications to the requested agent

AND

6. The requested dose is within FDA labeling

Length of Approval: 12 months

PRIOR AUTHORIZATION

Prior authorization is required for BlueCHiP for Medicare.

POLICY STATEMENT

BlueCHiP for Medicare

Gamifant™ (emapalumab-lzsg) is medically necessary when the criteria above have been met.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable physician administered drug benefits/coverage.

BACKGROUND

Hemophagocytic lymphohistiocytosis is an aggressive and life-threatening syndrome of excessive immune activation. Survival is dramatically increased with therapy and therapy should not be delayed due to specialized testing. Treatment may be begun on high clinical suspicion of diagnosis.

Historically, for clinical trials, diagnosis of primary HLH were confirmed through genetic testing or through confirmation of at least 5 of the following 8 findings:

- Fever $\geq 38.5^{\circ}\text{C}$
- Splenomegaly
- Peripheral blood cytopenia, with at least two of the following:
 - hemoglobin < 9 g/dL (for infants < 4 weeks, hemoglobin < 10 g/dL)
 - platelets $< 100,000/\text{microL}$
 - absolute neutrophil count $< 1000/\text{microL}$
- Hypertriglyceridemia (fasting triglycerides > 265 mg/dL) and/or hypofibrinogenemia (fibrinogen < 150 mg/dL)
- Hemophagocytosis in bone marrow, spleen, lymph node, or liver
- Low or absent NK cell activity
- Ferritin > 500 ng/mL (the author prefers to consider a ferritin > 3000 ng/mL as more indicative of HLH)
- Elevated soluble CD25 (soluble IL-2 receptor alpha [sIL-2R]) two standard deviations above age-adjusted laboratory-specific norms

UptoDate also lists the following as options to consider for diagnosing HLH:

- A patient with abnormality in 1 of the 4 immune markers (hemophagocytosis, increased ferritin, hypofibrinogenemia, absent or very decreased NK cell function) AND 3 of the 4 clinical findings (fever, splenomegaly, cytopenias, hepatitis)
- A patient with CNS symptoms, cytopenias, fever, and ferritin over 3000 ng/mL or rapidly rising ferritin or elevated sCD25
- A patient with CNS symptoms, hepatitis, coagulopathy, and ferritin over 3000 ng/mL or rapidly rising ferritin or elevated sCD25
- A patient with hypotension, fever, no response to broad spectrum antibiotics, and ferritin over 3000 ng/mL or rapidly rising ferritin or elevated sCD25

A scoring system has also been developed to predict the probability of HLH. A score of ≥ 250 implies a 99% probability of HLH.

Conventional therapy for HLH include immunosuppressive and pro-apoptotic chemotherapy (etoposide, corticosteroids, cyclophosphamide, cyclosporine, anti-thymocyte globulin, and methotrexate). Hematopoietic cell transplantation (HCT) is the curative therapy for HLH.

Emapalumab was studied in a multicenter, open-label, single arm trial of 27 pediatric patients with suspected or confirmed primary hemophagocytic lymphohistiocytosis (HLH). Patients' HLH were either refractory, recurrent, or progressive disease while on conventional HLH therapy or the patient was intolerant of conventional HLH therapy. The median duration of treatment with emapalumab was 59 days. Patients were required to fulfill the following criteria for enrollment:

1. Primary HLH based on a molecular diagnosis or family history consistent with primary HLH or through confirmation of 5 of the 8 clinical findings described above.
2. Patients had to have evidence of active disease as assessed by treating physician.
3. Patients had to fulfill one of the following criteria as assessed by the treating physician:
 - a. having not responded or not achieved a satisfactory response or not maintained a satisfactory response to conventional HLH therapy
 - i. Prior therapies in the trial included the following agents: dexamethasone, etoposide, cyclosporine A, and anti-thymocyte globulin
 - b. Intolerance to conventional HLH treatments.

For patients who are not receiving baseline dexamethasone treatment, begin dexamethasone at a daily dose of at least 5 to 10 mg/m² the day before emapalumab treatment begins. For patients who were receiving baseline dexamethasone, they may continue their regular dose provided the dose is at least 5 mg/m². Dexamethasone can be tapered according to the judgment of the treating physician.

CODING

BlueCHiP for Medicare

The following HCPCS code is covered when the medical criteria have been met:

J9210 Injection, emapalumab-lzsg, 1 mg

RELATED POLICIES

Prior Authorization of Drugs

PUBLISHED

Provider Update, August 2019

REFERENCES

1. Gamifant prescribing information. Novimmune S.A. November 2018.
2. Clinical features and diagnosis of hemophagocytic lymphohistiocytosis. UptoDate. Current through 2/2019. Last updated 10/29/2018.
3. Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. *Blood*. 2011;118(15):4041. Epub 2011 Aug 9.
4. Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. *Blood*. 2017;130(25):2728. Epub 2017 Sep 21.
5. Weitzman S. Approach to hemophagocytic syndrome. *Hematology*. 2011. Available at <https://www.histio.org/document.doc?id=295>.
6. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. *Arthritis and Rheumatology*. 2014 Sep;66(9):2613-20.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

